Literatur
-
1
di Bartolomeo M, Bajetta E, Buzzoni R. et al .
Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
Cancer.
1996;
77
402-408
-
2
Saltz L, Trochanowski B, Buckley M. et al .
Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.
Cancer.
1993;
72
244-248
-
3
Arnold R, Rinke A, Schmidt C. et al .
Endocrine tumours of the gastrointestinal tract: Chemotherapy.
Best Pract Res Clin Gastroenterol.
2005;
19
649-656
-
4
Moertel C G, Kvols L K, O’Connell M J. et al .
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
Cancer.
1991;
68
227-232
-
5
Mitry E, Rougier P.
The treatment of undifferentiated neuroendocrine tumors.
Crit Rev Oncol Hematol.
2001;
37
47-51
-
6
Hainsworth J D, Erland J B, Kalman L A. et al .
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
J Clin Oncol.
1997;
15
2385-2393
Dr. Ulrich Mey
Medizinische Klinik und Poliklinik I · Universitätsklinikum Bonn
Sigmund-Freud-Str. 25 · 53127 Bonn
Email: ulrich.mey@ukb.uni-bonn.de
